BrightInsight Inks Enterprise Agreement with CSL Behring for Digital Health Solutions Across Brand Portfolio SAN JOSE, Calif. and LAS VEGAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, today at...

Axtria Leads Discussion on Pharma’s Advanced Uses of Data Analytics and Artificial Intelligence With 6 Sessions at PMSA 2021 Annual Conference Berkeley Heights, NJ, June 16, 2021 (GLOBE NEWSWIRE) -- With the elevated importance of data analytics and artificial intelligence (AI)-driven intelligence technology systems for a global life...

uniQure announces closing of commercialization and license agreement with CSL Behring LEXINGTON, Mass. and AMSTERDAM, May 06, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy ~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~ ~ uniQure Eligible to Receive More Than $2 Billion,...

BrightInsight and CSL Behring Announce Global Digital Health Partnership to Improve Treatment Experience for Patients with Rare Diseases SAN JOSE, Calif. and KING OF PRUSSIA, Pa., May 06, 2020 (GLOBE NEWSWIRE) -- BrightInsight, Inc., the provider of the leading regulated IoT platform for biopharma and medtech, and CSL Behring, a...